Eva Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eva Jones has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Davies
School of Medicine, Trinity College Dublin, Dublin, Ireland
1 shared publication - Aoibheann Conneely
Department of Palliative Medicine, St James's Hospital , Dublin
1 shared publication Bettina Korn
Department of Nursing, St James's Hospital , Dublin
1 shared publicationCiara Anderson
Department of Infectious Diseases, St James's Hospital , Dublin
1 shared publicationCiaran Bannan
Department of Infectious Diseases, St James's Hospital , Dublin
1 shared publication- Faith Precious Omeokwe
School of Nursing, George Washington University, Ashburn, USA
1 shared publication
Latest Publications
- Open Access
- 7 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6) , 516
The clinical relevance of sleep disturbance (“insomnia”) in patients with advanced cancer receiving palliative care: a scoping review
Purpose: Sleep disturbance (“insomnia”) is common in patients with advanced cancer receiving specialist palliative care. The aim of this scoping review was to determine the clinical relevance of sleep disturbance in this cohort of patients. Methods: Standard methodology was employed, and four databases were searched from inception (Medline, CINAHL, Embase, and APA PsycInfo). Hand searching of relevant sources was also undertaken. Included studies needed to have a sleep focus, and to utilise a validated sleep assessment tool (and/or objective measure of sleep quality). Results: Sixteen studies met the criteria for inclusion. The studies highlight that sleep disturbance is associated with a range of physical symptoms (e.g. fatigue, drowsiness), a variety of psychological problems (e.g. anxiety, depression), impaired quality of life, and reduced overall survival. Conclusion: Sleep disturbance is an “orphan” symptom, and the results of this scoping review suggest that it deserves much greater attention. Indeed, healthcare professionals should screen all palliative care patients for the problem and, when identified, perform a thorough assessment and initiate an appropriate treatment.
- 7 May 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (6) , 516
Open AccessThe clinical relevance of sleep disturbance (“insomnia”) in patients with advanced cancer receiving palliative care: a scoping review
Purpose: Sleep disturbance (“insomnia”) is common in patients with advanced cancer receiving specialist palliative care. The aim of this scoping review was to determine the clinical relevance of sleep disturbance in this cohort of patients. Methods: Standard methodology was employed, and four databases were searched from inception (Medline, CINAHL, Embase, and APA PsycInfo). Hand searching of relevant sources was also undertaken. Included studies needed to have a sleep focus, and to utilise a validated sleep assessment tool (and/or objective measure of sleep quality). Results: Sixteen studies met the criteria for inclusion. The studies highlight that sleep disturbance is associated with a range of physical symptoms (e.g. fatigue, drowsiness), a variety of psychological problems (e.g. anxiety, depression), impaired quality of life, and reduced overall survival. Conclusion: Sleep disturbance is an “orphan” symptom, and the results of this scoping review suggest that it deserves much greater attention. Indeed, healthcare professionals should screen all palliative care patients for the problem and, when identified, perform a thorough assessment and initiate an appropriate treatment.
- Open Access
- 30 October 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Factors Influencing Antimicrobial Choice and Duration During the Last Month of Life in Hospitalized Patients
Background: Antimicrobial prescribing in patients approaching end of life is complex. We aimed to describe antimicrobial use in the final 4 weeks of life among hospitalized patients and identify factors associated with antimicrobial consumption. Methods: We conducted a retrospective review of antimicrobial use among inpatients during their last 4 weeks of life in a tertiary Irish hospital. Data collected included antimicrobial agents and duration of therapy, microbiological sampling, infection services input, palliative care services input, patient demographics, frailty scores, and markers of inflammation. Univariate analysis and multivariable linear regression were used to assess factors associated with antimicrobial-free time before death. Results: Two hundred and fifty-eight patients were included, with 91% receiving antimicrobials during the study period. Only 36% had a presumed infection at the time of admission. Antimicrobial use was characterized by broad-spectrum agents, did not correlate with culture results, and had a median duration (interquartile range) of 10.5 (5–18) days. Palliative care consultation (P = .004) and longer length of stay (P < .0001) were associated with a longer antimicrobial-free interval before death. Within the antimicrobial cohort, 26% developed acute kidney injury. Cessation of antimicrobial therapy often occurred late, with 40% of patients receiving antimicrobial therapy within 24 hours of death. Conclusions: There was a high burden of antimicrobial use in patients nearing the end of life, characterized by broad-spectrum, empiric therapy, often continued until hours before death. We recommend expansion of antimicrobial surveillance and collaboration between infection and palliative care services in order to optimize and rationalize antimicrobial prescribing in patients approaching end of life.
- 30 October 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Open AccessFactors Influencing Antimicrobial Choice and Duration During the Last Month of Life in Hospitalized Patients
Background: Antimicrobial prescribing in patients approaching end of life is complex. We aimed to describe antimicrobial use in the final 4 weeks of life among hospitalized patients and identify factors associated with antimicrobial consumption. Methods: We conducted a retrospective review of antimicrobial use among inpatients during their last 4 weeks of life in a tertiary Irish hospital. Data collected included antimicrobial agents and duration of therapy, microbiological sampling, infection services input, palliative care services input, patient demographics, frailty scores, and markers of inflammation. Univariate analysis and multivariable linear regression were used to assess factors associated with antimicrobial-free time before death. Results: Two hundred and fifty-eight patients were included, with 91% receiving antimicrobials during the study period. Only 36% had a presumed infection at the time of admission. Antimicrobial use was characterized by broad-spectrum agents, did not correlate with culture results, and had a median duration (interquartile range) of 10.5 (5–18) days. Palliative care consultation (P = .004) and longer length of stay (P < .0001) were associated with a longer antimicrobial-free interval before death. Within the antimicrobial cohort, 26% developed acute kidney injury. Cessation of antimicrobial therapy often occurred late, with 40% of patients receiving antimicrobial therapy within 24 hours of death. Conclusions: There was a high burden of antimicrobial use in patients nearing the end of life, characterized by broad-spectrum, empiric therapy, often continued until hours before death. We recommend expansion of antimicrobial surveillance and collaboration between infection and palliative care services in order to optimize and rationalize antimicrobial prescribing in patients approaching end of life.